A comparison of tiotropium, long-acting β2-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma.
In conclusion, this literature review provides an up-to-date overview of the efficacy and safety of LABAs, LTRAs and LAMAs as add-on to ICS in children and adolescents with asthma. Overall, tiotropium and LABAs have similar efficacy, and provide greater improvements in lung function than montelukast as add-on to ICS. All three controller options have comparable safety profiles.
PMID: 31931792 [PubMed - in process]
Source: Respiratory Care - Category: Respiratory Medicine Authors: Vogelberg C, Goldstein S, Graham L, Kaplan A, de la Hoz A, Hamelmann E Tags: Respir Res Source Type: research
More News: Asthma | Children | Corticosteroid Therapy | Pediatrics | Respiratory Medicine | Spiriva | Study | Tiotropium